These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33892057)

  • 1. Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.
    Chu Y; Qin C; Feng W; Sheriston C; Jane Khor Y; Medrano-Padial C; Watson BE; Chan T; Ling B; Stocks MJ; Fischer PM; Gershkovich P
    Int J Pharm; 2021 Jun; 602():120621. PubMed ID: 33892057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach.
    Qin C; Chu Y; Feng W; Fromont C; He S; Ali J; Lee JB; Zgair A; Berton M; Bettonte S; Liu R; Yang L; Monmaturapoj T; Medrano-Padial C; Ugalde AAR; Vetrugno D; Ee SY; Sheriston C; Wu Y; Stocks MJ; Fischer PM; Gershkovich P
    J Control Release; 2021 Jan; 329():1077-1089. PubMed ID: 33091528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport.
    Chu Y; Wong A; Chen H; Ji L; Qin C; Feng W; Stocks MJ; Gershkovich P
    Eur J Pharm Biopharm; 2023 Oct; 191():90-102. PubMed ID: 37634824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid.
    Han S; Quach T; Hu L; Lim SF; Zheng D; Leong NJ; Sharma G; Bonner D; Simpson JS; Trevaskis NL; Porter CJH
    Mol Pharm; 2023 May; 20(5):2675-2685. PubMed ID: 36996486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of lamivudine into lymph node HIV reservoir.
    Wong A; Chu Y; Chen H; Feng W; Ji L; Qin C; Stocks MJ; Marlow M; Gershkovich P
    Int J Pharm; 2023 Dec; 648():123574. PubMed ID: 37935311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
    Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
    J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.
    Lee JB; Zgair A; Malec J; Kim TH; Kim MG; Ali J; Qin C; Feng W; Chiang M; Gao X; Voronin G; Garces AE; Lau CL; Chan TH; Hume A; McIntosh TM; Soukarieh F; Al-Hayali M; Cipolla E; Collins HM; Heery DM; Shin BS; Yoo SD; Kagan L; Stocks MJ; Bradshaw TD; Fischer PM; Gershkovich P
    J Control Release; 2018 Sep; 286():10-19. PubMed ID: 30016732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220.
    Gershkovich P; Qadri B; Yacovan A; Amselem S; Hoffman A
    Eur J Pharm Sci; 2007 Aug; 31(5):298-305. PubMed ID: 17560096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
    Yeni P
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine.
    Xie Y; Lu Z; Styles IK; Reddiar SB; Phillips ARJ; Windsor JA; Porter CJH; Han S; Trevaskis NL
    J Pharm Sci; 2024 Aug; 113(8):2342-2351. PubMed ID: 38582284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
    Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
    BMC Infect Dis; 2009 Sep; 9():154. PubMed ID: 19751502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
    Mehandru S; Markowitz M
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1821-8. PubMed ID: 14585057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
    Allavena C; Flandre P; Pugliese P; Valantin MA; Poizot-Martin I; Cabié A; Melliez H; Cuzin L; Duvivier C; Dellamonica P; Raffi F;
    Scand J Infect Dis; 2012 Jan; 44(1):37-43. PubMed ID: 21851330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
    AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity.
    Ye J; Gao Y; Ji M; Yang Y; Wang Z; Wang B; Jin J; Li L; Wang H; Xu X; Liao H; Lian C; Xu Y; Li R; Sun T; Gao L; Li Y; Chen X; Liu Y
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.